LTFS
JUNO

Ladenburg Thalmann Financial Services’s Juno Therapeutics, Inc. JUNO Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8,422
Closed -$385K – 5332
2017
Q4 		$385K Buy
8,422
+2,220
+36% +$111K ﹤0.01% 1726
2017
Q3 		$277K Buy
6,202
+133
+2% +$4.53K ﹤0.01% 1860
2017
Q2 		$182K Buy
6,069
+3,169
+109% +$78.2K ﹤0.01% 2093
2017
Q1 		$64K Buy
2,900
+1,200
+71% +$25.7K ﹤0.01% 2720
2016
Q4 		$32K Sell
1,700
-1,744
-51% -$42.7K ﹤0.01% 3171
2016
Q3 		$104K Buy
3,444
+793
+30% +$24.7K ﹤0.01% 2229
2016
Q2 		$102K Buy
2,651
+231
+10% +$9.59K ﹤0.01% 2153
2016
Q1 		$92K Sell
2,420
-50
-2% -$1.74K ﹤0.01% 2130
2015
Q4 		$109K Buy
2,470
+70
+3% +$3.47K ﹤0.01% 1999
2015
Q3 		$97K Buy
2,400
+950
+66% +$41.7K ﹤0.01% 2021
2015
Q2 		$78K Sell
1,450
-4,887
-77% -$259K ﹤0.01% 2284
2015
Q1 		$385K Buy
6,337
+2,087
+49% +$101K 0.01% 1180
2014
Q4 		$222K Buy
+4,250
New +$190K ﹤0.01% 1353

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Ladenburg Thalmann Financial Services's JUNO Position: Q1 2018 in Review

Ladenburg Thalmann Financial Services sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 8,422 shares — an estimated $385K sold.

Ladenburg Thalmann Financial Services first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $385K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Ladenburg Thalmann Financial Services reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 8,422 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $385K.
  • Ladenburg Thalmann Financial Services first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Ladenburg Thalmann Financial Services's Juno Therapeutics, Inc. position peaked at $385K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2018, filed 15 May 2018.